LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Clinical trials for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL explained in plain language.
Never miss a new study
Get alerted when new LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL trials appear
Sign up with your email to follow new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a treatment called JCAR017, which uses a patient's own immune cells that are modified in a lab to better find and attack cancer cells. It is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1, PHASE2 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New hope for blood cancer patients: drug combo aims to control relapsed CLL
Disease control Recruiting nowThis study tests whether a new drug, nemtabrutinib, combined with venetoclax works better than the standard venetoclax plus rituximab for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to treatment. Abou…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a treatment called anti-CD19 CAR T-cell therapy for people with advanced B-cell leukemias or lymphomas that haven't responded to standard drugs. Participants' own immune cells are collected, modified to recognize and attack cancer cells, and then returned to the …
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New study tailors leukemia drug dosing to reduce side effects
Disease control Recruiting nowThis study looks at different ways to give the drug ibrutinib to people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Some participants will also get another drug called venetoclax. The goal is to see if lowering the dose early or changing it based on…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
Exercise boosts Well-Being in leukemia patients on targeted therapy
Symptom relief Recruiting nowThis study looks at whether a custom exercise plan can help people with chronic lymphocytic leukemia (CLL) who are starting the drug ibrutinib feel better in their daily lives. About 180 adults will be asked to follow a personalized physical activity program and wear a connected …
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Sponsor: Janssen Cilag S.A.S. • Aim: Symptom relief
Last updated May 13, 2026 16:03 UTC
-
Can your genes predict blood cancer? mayo clinic launches massive family study
Knowledge-focused Recruiting nowThis study looks at why some families have more blood cancers like lymphoma, leukemia, and myeloma. Researchers will study the genes and environment of 3000 people who have at least two living relatives with these cancers. The goal is to find inherited factors that raise risk, no…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 04, 2026 16:31 UTC